Drug Profile


Alternative Names: Citoplurikin; IRX-2

Latest Information Update: 17 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IRX Therapeutics
  • Developer IRX Therapeutics; Providence Health & Services; University of Southern California
  • Class Antineoplastics; Cytokines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cervical intraepithelial neoplasia; Head and neck cancer; Vulvar intraepithelial neoplasia
  • Phase I Breast cancer

Most Recent Events

  • 07 Sep 2018 National Cancer Institute plans a phase I trial for Liver cancer (Combination therapy, Late-stage disease, Second-line or greater therapy) in USA (NCT03655002)
  • 02 Jul 2018 Bristol-Myers Squibb in collaboration with IRX Therapeutics plans a phase I/II trial for Oropharyngeal-cancer (Neo-adjuvant therapy, combination therapy) in USA , (NCT03575234)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top